Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 August 2008, Vol. 112, No. 4, pp. 1374-1381.
Prepublished online as a Blood First Edition Paper on May 28, 2008; DOI 10.1182/blood-2008-01-136465.


This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Tables and Figures
Right arrow All Versions of this Article:
blood-2008-01-136465v1
112/4/1374    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klapper, W.
Right arrow Articles by Siebert, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klapper, W.
Right arrow Articles by Siebert, R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted January 28, 2008
Accepted May 3, 2008

Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials

Wolfram Klapper*, Monika Szczepanowski, Birgit Burkhardt, Hilmar Berger, Maciej Rosolowski, Stefan Bentink, Carsten Schwaenen, Swen Wessendorf, Rainer Spang, Peter Moller, Martin Leo Hansmann, Heinz-Wolfram Bernd, German Ott, Michael Hummel, Harald Stein, Markus Loeffler, Lorenz Trumper, Martin Zimmermann, Alfred Reiter, and Reiner Siebert

Department of Pathology, Hematopathology Section and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
Children’s University Hospital, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
Institute of Functional Genomics, University of Regensburg, Regensburg, Germany
Cytogenetic and Molecular Diagnostics, Internal Medicine III, University Hospital of Ulm, Ulm, Germany
Institute of Pathology, University Hospital of Ulm, Ulm, Germany
Institute of Pathology, University of Frankfurt, Frankfurt, Germany
Institute of Pathology, University Hospital Schleswig-Holstein, Campus Lubeck, Lubeck, Germany
Institute of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany
Institute of Pathology, Campus Benjamin Franklin, Charite Universitatsmedizin, Berlin, Germany
Department of Hematology and Oncology, Georg-August University of Gottingen, Gottingen, Germany
Department of Pediatric Hematology and Oncology, University of Hannover, Germany
NHL-BFM Study Center, Department of Pediatric Hematology and Oncology, Justus-Liebig-University, Giessen, Germany
Institute of Human Genetics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

* Corresponding author; email: wklapper{at}path.uni-kiel.de.

The spectrum of entities, the therapeutic strategy and the outcome of mature aggressive B-cell Non-Hodgkin lymphomas (maB-NHL) differs between children and adolescents on the one hand and adult patients on the other. Whereas adult maB-NHL have been studied in detail, data on molecular profiling of pediatric maB-NHL are hitherto lacking. We analyzed 65 cases of maB-NHL from patients up to 18 years of age by gene expression profiling, matrix CGH, FISH and immunohistochemistry. The majority of the analyzed pediatric patients were treated within prospective trials (n=49). We compared this group to a series of 182 previously published cases of adult maB-NHL. Gene expression profiling reclassified 31% of morphologically defined diffuse large B-cell lymphomas as molecular Burkitt lymphoma (mBL). The subgroups obtained by molecular reclassification did not show any difference in outcome in children treated with the NHL-BFM protocols. No differences were detectable between pediatric and adult mBL with regard to gene expression or chromosomal imbalances. This is the first report on molecular profiling of pediatric B-NHL showing mBL to be much more prominent in children than suggested by morphological assessment. Based on molecular profiling mBL is a molecularly homogeneous disease across children and adults.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Brief Funct Genomic ProteomicHome page
U. Bacher, A. Kohlmann, and T. Haferlach
Perspectives of gene expression profiling for diagnosis and therapy in haematological malignancies
Brief Funct Genomic Proteomic, May 27, 2009; (2009) elp011v1.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020